Octave Specialty (OSG) Cash & Equivalents (2010 - 2026)

Octave Specialty's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $93.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 81.06% year-over-year to $93.5 million; the TTM figure through Mar 2026 stood at $93.5 million (up 81.06% YoY), while the FY2025 annual figure was $68.4 million, up 44.77% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $93.5 million, up from $68.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $309.0 million in Q2 2023, with the low at $19.2 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $51.7 million (2025), against an average of $94.9 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 694.74% in 2023, then tumbled 91.88% in 2024.
• Octave Specialty's Cash & Equivalents stood at $19.9 million in 2022, then slipped by 3.6% to $19.2 million in 2023, then soared by 145.93% to $47.3 million in 2024, then soared by 44.77% to $68.4 million in 2025, then surged by 36.67% to $93.5 million in 2026.
• Business Quant data shows OSG's Cash & Equivalents at $93.5 million in Q1 2026, $68.4 million in Q4 2025, and $51.8 million in Q3 2025.